Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1

Conditions

Leukemia, Myeloid, Acute 2Blastic Plasmacytoid Dendritic Cell Neoplasm 2Recurrence 1Primary Myelofibrosis 1Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Multiple Myeloma 1Leukemia, Myelomonocytic, Chronic 1Burkitt Lymphoma 1

Interventions

Cyclophosphamide 130Methotrexate 93fludarabine phosphate 74Cytarabine 71Vincristine 66Whole-Body Irradiation 65Mycophenolic Acid 58Dexamethasone 55Tacrolimus 49Peripheral Blood Stem Cell Transplantation 48fludarabine 47Busulfan 46pegaspargase 43Filgrastim 41Etoposide 41Doxorubicin 41Calcium Dobesilate 40Granulocyte Colony-Stimulating Factor 39Rituximab 36Cyclosporine 36Mercaptopurine 35Melphalan 33Prednisone 31merphos 28Clofarabine 26Asparaginase 26Antilymphocyte Serum 25Leucovorin 23Daunorubicin 23Thiotepa 22

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Precursor Cell Lymphoblastic Leukemia-Lymphoma × tagraxofusp × Clear all
NCT05032183 2025-08-11

Tagraxofusp and Low-Intensity Chemotherapy for the Treatment of CD123 Positive Relapsed or Refractory Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma

M.D. Anderson Cancer Center

Phase 1/2 Terminated
4 enrolled 8 charts
LymphoidOther hematologic neoplasm

Burkitt Lymphoma, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡